Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B.
OBJECTIVE
Despite the possible role of adiponectin in the pathogenesis of liver cirrhosis, few data have been collected from patients in different stages of liver fibrosis. We studied the role of adiponectin in 2 chronic hepatitis B (CHB)-patient cohorts.


METHODS
Serum adiponectin was quantified by enzyme-linked immunosorbent assay. One-hundred liver biopsy specimens from CHB patients with different stages of fibrosis and 38 paired liver biopsies from hepatitis B e antigen-positive patients randomized to lamivudine (n=15), pegylated interferon alfa-2a (n=15) or pegylated interferon alfa-2a plus lamivudine (n=8) therapy for 48 weeks were assessed.


RESULTS
Serum adiponectin was detected at levels ranging over fourfold magnitude with advancing fibrosis stage and correlated positively with fibrosis stage [r=0.45, p<0.001]. CHB patients with stage 0-1 fibrosis had higher composition of high molecular weight (HMW) form of adiponectin when compared with CHB patients with liver cirrhosis [mean+/-SEM 51.2+/-2.1% vs. 40.9+/-1.7%, respectively, p=0.001]. After antiviral therapy, patients with fibrosis reduction had marked decline in serum adiponectin level and increase in HMW form of adiponectin [mean+/-SEM 43.5+/-1.2% vs. 37.0+/-3.0%, respectively, p=0.04].


CONCLUSIONS
Serum adiponectin may have a role in fibrosis progression in CHB infection. A marked decline in serum adiponectin after antiviral therapy is associated with fibrosis reduction.
Hui
Chee-Kin
CK
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China. ckhui23@gmail.com
Zhang
Hai-Ying
HY
Lee
Nikki P
NP
Chan
Weng
W
Yueng
Yui-Hung
YH
Leung
Kar-Wai
KW
Lu
Lei
L
Leung
Nancy
N
Lo
Chung-Mau
CM
Fan
Sheung-Tat
ST
Luk
John M
JM
Xu
Aimin
A
Lam
Karen S
KS
Kwong
Yok-Lam
YL
Lau
George K K
GK
D052242:Adiponectin / Q000097:blood* / Q000737:chemistry / Q000235:genetics; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use; D015331:Cohort Studies; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008099:Liver / Q000378:metabolism; D008103:Liver Cirrhosis / Q000097:blood* / Q000378:metabolism / Q000473:pathology* / Q000821:virology; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012720:Severity of Illness Index
D052242:Adiponectin; D000998:Antiviral Agents; D012333:RNA, Messenger